Health Canada expands approval of Enhertu for adults with HER2 positive metastatic breast cancer

23 June 2022 - Approval based on the ground-breaking DESTINY-Breast03 Phase 3 trial, showing Enhertu reduced the risk of disease ...

Read more →

Maviret (glecaprevir/pibrentasvir) approved by Health Canada for paediatric patients with chronic hepatitis C

22 June 2022 - This approval is supported by 98.4 per cent cure rate across this group of patients who ...

Read more →

Canadian regulator OKs Hugel's botulinum toxin product

16 June 2022 - Hugel said Thursday that it has obtained product approval from Health Canada for its botulinum toxin ...

Read more →

Canadian drug prices: new regulations could save billions of dollars

15 June 2022 - New drug price regulations set to come into effect next month could lower spending on patented ...

Read more →

Core network partners announced for CADTH’s post-market drug evaluation network

10 June 2022 - CADTH is pleased to announce the four successful core network partners of its inaugural post-market drug ...

Read more →

Amylyx Pharmaceuticals announces Health Canada approval of Albrioza for the treatment of ALS

13 June 2022 - Health Canada decision signifies the first global regulatory approval for Amylyx and the first new therapy for ...

Read more →

Health Canada approves Tabrecta: targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations

8 June 2022 - Newest treatment for lung cancer reinforces Novartis commitment to developing innovative therapies that improve outcomes for ...

Read more →

The UK MHRA, Australian TGA and Health Canada approve Kimmtrak (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

8 June 2022 - Kimmtrak demonstrated statistically and clinically meaningful overall survival benefit, hazard ratio of 0.51, with median overall survival ...

Read more →

Forus Therapeutics announces Xpovio (selinexor) is authorised for sale by Health Canada

7 June 2022 - FORUS Therapeutics is pleased to announce that on 31 May 2022, Xpovio (selinexor) was authorised for ...

Read more →

BioCryst announces Health Canada has authorised Orladeyo (berotralstat), the only oral treatment for the prevention of hereditary angioedema attacks

6 June 2022 - BioCryst Pharmaceuticals today announced that Health Canada has approved oral, once daily Orladeyo (berotralstat) for the ...

Read more →

Health Canada OKs Pfizer COVID-19 booster shot for teens ages 16 and 17

1 June 2022 - Canada on Wednesday authorised a single booster shot of Pfizer and partner BioNTech’s COVID-19 vaccine for ...

Read more →

Health Canada authorises Vabysmo (faricimab injection) for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular oedema

1 June 2022 - Vabysmo (faricimab injection) is the first bispecific antibody that acts by neutralising both VEGF-A and Ang-2 ...

Read more →

Bausch + Lomb receives Health Canada approval of Lumify redness reliever eye drops

24 May 2022 - Lumify is Canada's first and only over the counter eye drop with low dose brimonidine for ...

Read more →

HLS Therapeutics obtains public reimbursement for Vascepa in Quebec

24 May 2022 - Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with ...

Read more →

Draft CADTH recommendation for Spinraza (nusinersen sodium) fails adults in need of treatment for spinal muscular atrophy

20 May 2022 - CADTH does not accept new evidence demonstrating Spinraza's effectiveness and safety for treating spinal muscular atrophy – ...

Read more →